Single Crystal Structure Elucidation

Are you facing challenges getting reliable single crystal structures of APIs or intermediate compounds? You can get professional help from our leading crystallization expert with decades of successful experiences from BMS and the Center for Pharma Crystallization (CfPC) at J-Star Research.

CfPC at J-Star Research

See how the Center for Pharma Crystallization (CfPC) at J-Star Research is effectively supporting new drug development programs.

Solid Form Studies – CfPC July 2021

Cure the pains caused by polymorphs, working with The Center for Pharma Crystallization (CfPC) at J-Star Research.

Preformulation Strategy – Inception to Completion

Drug discovery is an exceedingly complex process. Discovering a new chemical entity is in itself a huge accomplishment, which is often possible only after almost two decades of hard experimental work as well as advanced simulation efforts.

A Challenging Path to Controlled Nano-API Crystallization and Isolation

Controlled crystallization of an API in submicron size was enabled based on an accurate solubility profile and a growth inhibition property via semi-continuous processing, to meet special formulation requirements.

Addressing Bottleneck Problems in Crystallization R&D for New Drug Development

Diverse crystallization challenges encountered by CfPC (Center for Pharma Crystallization) and our clients will be analyzed systematically to provide insights into main bottleneck problems in today’s drug development programs.

Pharmaceutical Crystallization Support by Computational Approaches

Given challenges facing the pharmaceutical industry, an accelerated Drug Development greatly benefits from guidance provided by computational methods. This presentation will focus on computational support of the following important tasks related to the pharmaceutical crystallization.

2020 Pharmaceutical Crystallization Summit Report

Crystallization technologies are bridges between drug substances (DS) and drug products (DP) enabling consistent and robust safety and efficacy profiles of small molecule based medicines.

Integrative Approaches to Addressing Canonical Problems in Pharmaceutical Crystallization

Problems associated with polymorphic instability and increasingly insoluble drug candidates represent white space to innovate novel forms and processing methods with better properties in the drug product. But the journey from identifying new solid forms to creating engineered particles with optimal formulation properties has often been too inefficient to realize this goal.

Computation Assisted Solvent Selection in Crystal Form Investigation

Rational selection of solvents plays a critical role in solid form screening and production. On the one hand, a variety of solvents with different properties are chosen in form screening to maximize the screening space of searching for all potential solid forms because some solvents selectively favor the generation of a particular form as a result of crystallization kinetics.